Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 3/20 | 0.49 |
| ▸ | FNTB | P49356 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.48 |
| ▸ | SQLE | Q14534 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11574425 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL11575896 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL11574815 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL12281204 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL11575551 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL11575899 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL1564345 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL10297988 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL10490785 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A | |
| SCHEMBL12457084 | 1.00 | KDM4E (0.55) | KDM4EATMALDH1A1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112601737-B | Method for synthesizing vitamin A | 安迪苏法国联合股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| EP-3841089-B1 | METHOD FOR SYNTHESISING VITAMIN A | ADISSEO FRANCE SAS (FR) | 2022-10-12 | — | — | EP | claimed |
| CN-101184532-A | Reduction of hair growth | GILLETTE CO (US) | 2008-05-21 | — | — | CN | claimed |
| US-20060035873-A1 | Methods for inducing apolipoprotein e secretion | ILEX PRODUCTS, INC. | 2006-02-16 | — | — | US | claimed |
| EP-4267547-B1 | PROCESS OF MAKING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-02-05 | — | — | EP | disclosed |
| US-20240051904-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-112585117-B | Method for synthesizing vitamin A | 安迪苏法国联合股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-116601136-A | Method for producing organic compound | 奇华顿股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-112601737-B | Method for synthesizing vitamin A | 安迪苏法国联合股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3841089-B1 | METHOD FOR SYNTHESISING VITAMIN A | ADISSEO FRANCE SAS (FR) | 2022-10-12 | — | — | EP | disclosed |
| CN-110903190-B | Preparation method of vitamin A and vitamin A ester | 万华化学集团股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11365169-B2 | Method for synthesising vitamin A | ADISSEO FRANCE S.A.S. (FR) | 2022-06-21 | — | — | US | disclosed |
| US-4123465-A | SELECTIVE HYDROGENATION CATALYSTS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-31 | — | — | US | disclosed |
| US-4115417-A | ENANTIOSELECTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051904-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | FDPS, HMGCR, SQLE | KDM4E 4051/4885ATM 4352/4885ALDH1A1 513/4885 |
| US-11365169-B2 | Method for synthesising vitamin A | CYP2R1, NR1H3, NR1H2 | KDM4E 3310/4885ATM 3877/4885ALDH1A1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.